$1,000 invested in Mesoblast shares at the start of 2024 is now worth…

Did this biotech company deliver the goods for investors? Let's see what a $1,000 investment would be worth.

| More on:
Person holding Australian dollar notes, symbolising dividends.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Mesoblast Ltd (ASX: MSB) shares have been on an incredible run over the past 12 months.

So much so, you would be laughing all the way to the bank if you had bought the biotechnology company's shares at the start of 2024.

Let's see what a $1,000 investment in the company's shares would be worth now.

$1,000 invested into Mesoblast shares

At the start of 2024, investors were able to pick up the company's shares for 31 cents.

This means that with a $1,000 investment, you would have ended up owning 3,226 Mesoblast shares.

Today, the stem cell therapy developer's shares are worth significantly more than the start of 2024 and closed yesterday's session at $3.06.

This means that those 3,226 shares have a market value of $9,871.56.

That's a staggering return on investment of approximately $8,871 after just a touch over 12 months.

But how did we get here? Let's dig a little deeper into things.

Why did its shares rocket?

It is worth noting that at the start of 2024, things were looking very uncertain for Mesoblast.

The company had been knocked back multiple times from the US FDA when attempting to get its stem cell therapies approved.

This led to management having to raise funds countless times over the past decade to keep the lights on. But its perseverance paid off, with regulators in the US finally changing their tune and approving its Ryoncil (remestemcel-L) product as the first mesenchymal stromal cell (MSC) therapy in the US in December last year.

Ryoncil is the only MSC therapy approved in the U.S. for any indication, and the only approved therapy for steroid-refractory acute graft versus host disease (SR-aGvHD) in children two months and older. This includes adolescents and teenagers.

SR-aGvHD is a life-threatening condition with high mortality rates. Annually in the United States there are approximately 10,000 patients that undergo an allogeneic bone marrow transplant, 1,500 of whom are children.

This approval has sparked hopes that Mesoblast's other stem cell therapies could soon be approved, putting the company in a position to generate significant revenues in the coming years. Mesoblast's chief executive, Dr. Silviu Itescu, said:

With RYONCIL approval by FDA, Mesoblast has demonstrated the ability to bring the first MSC product to market. We will continue to work closely with FDA to obtain approval of our other late-stage products, including REVASCOR for cardiovascular diseases and rexlemestrocel-L for inflammatory pain indications, as well as expanding the indications for RYONCIL in both children and adults with inflammatory conditions.

Can its shares keep rising?

Bell Potter still sees scope for Mesoblast's shares to keep rising. Its analysts recently put a speculative buy rating and $3.90 price target on them. It said:

The approval of Ryoncil has been transformational for the company with an exciting pipeline of products to follow. We retain our Buy (Spec) rating with valuation increased to $3.90 (from $1.40) owing largely to the de-risking of future revenues.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A hipster dude leaps in the air with glee, seeing positive news on his tablet.
Healthcare Shares

Which ASX 200 stock is jumping 11% on big news?

Investors are responding very positively to a big announcement.

Read more »

Senior woman using cpap machine to stop choking and snoring from obstructive sleep apnoea with bokeh and morning light background.
Healthcare Shares

Up more than 75% since October 2023 — are ResMed shares a buy, hold or sell?

ResMed shares have surged more than 75% since October 2023, but is it too late to buy? We break down…

Read more »

Stethoscope with a piggy bank in the middle.
Broker Notes

Australian health insurance: Does Macquarie prefer Medibank or NIB shares?

Medibank and NIB shares have both surged in 2025. Here’s what Macquarie expects now.

Read more »

Two brokers analysing stocks.
Healthcare Shares

Why does Macquarie think Fisher & Paykel shares are a buy?

Fisher & Paykel Healthcare Corporation Ltd (ASX: FPH) shares have been on form over the past 12 months. During this…

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Which small cap ASX share is jumping 10% on strong results

Investors have been bidding this stock higher today. But why?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why Macquarie forecasts 30-50% upside for these ASX All Ords healthcare stocks

Macquarie updated its target price on these three ASX All Ords healthcare stocks.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Guess which ASX 200 stock is jumping 10% on big news

This stock is catching the eye with a strong gain on Thursday. But why?

Read more »

a young woman holds her hand to her ear and leans sideways as if to listen to something that's surprising her as her eyes and her mouth are wide open.
Healthcare Shares

Down 15% since January, are Cochlear shares now a buy?

Let's see what analysts are saying about this blue chip.

Read more »